In the first in-human phase I trial for Teliso-V, NSCLC patients with
MET-overexpressing tumors received monotherapy. The results of this innovative
trial indicated favorable safety and tolerability responses and also showed promising
antitumor activity in NSCLC patients with MET overexpression.
